UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,174.01
    +182.61 (+0.91%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

Vaccine Dealmaking 2014-2020: Global Terms & Agreements, Deal Trends, Players and Financials - ResearchAndMarkets.com

·3-min read

DUBLIN, December 08, 2021--(BUSINESS WIRE)--The "Global Vaccine Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in vaccine dealmaking in the biopharma industry since 2014

  • Analysis of vaccine deal structure

  • Access to headline, upfront, milestone and royalty data

  • Access to over 1000 vaccine deal documents

  • The leading vaccine deals by value since 2014

  • Most active vaccine dealmakers since 2014

  • The leading vaccine partnering resources

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 1000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

In the report, the available contracts are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Therapy target

  • Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report provides comprehensive access to available deals and contract documents for over 1000 vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise vaccine rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

The report provides the reader with the following key benefits:

  • In-depth understanding of vaccine and adjuvant deal trends since 2014

  • Access to headline, upfront, milestone and royalty data

  • Comprehensive access to over 1000 actual vaccine deals entered into by the world's biopharma companies, together with contract documents if available

  • Detailed access to actual vaccine contracts enter into by leading bio pharma companies

  • Identify leading vaccine deals by value since 2014

  • Identify the most active vaccine dealmakers since 2014

  • Insight into the terms included in a vaccine agreement

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Companies Mentioned

  • 2A

  • 3D Medicines

  • 3SBio

  • 4D Pharma

  • A*STAR' Institute of Molecular and Cell Biology

  • ABEC

  • ABIVAX

  • AGC Biologics

  • Agenus Bio

  • Agilvax

  • AIM ImmunoTech

  • Akers Biosciences

  • Amyris

  • Analytical Bio-Chemistry Laboratories

  • AnGes MG

  • Anixa Biosciences

  • Battelle

  • Batu Biologics

  • CCT Research

  • Celldex Therapeutics

  • Cellular Biomedicine

  • Celonic

  • Diavax Biosciences

  • Diaxonhit

  • DNA Script

  • DNAtrix

  • Dr. Reddy's Laboratories

  • Frederick National Laboratory For Cancer Research

  • Fred Hutchinson Cancer Research Center

  • Fujifilm

  • GISCAD Foundation

  • GlaxoSmithKline

  • Hefei Sageland Biotechnology

  • Helmholtz Zentrum Munchen

  • MinervaX

  • Recipharm

  • Sanofi

  • Wyss Institute

  • Xenetic Biosciences

  • XstalBio

  • Y-Biologics

  • Y-mAbs Therapeutics

  • Yale University

  • Yamaguchi University

  • Yisheng Biopharma

  • Zenoaq

  • Zoetis

  • Zolovax

  • Zuellig Pharma China

  • Zydus Cadila

  • ZYUS Life Sciences

  • and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/cmrgks

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005506/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting